Pfizer INC Form 4 insider transactions

Executive Vice President Michael McDermott reported the earn-out of stock appreciation rights and related tax and exercise price obligations resulting in changes to his beneficial ownership of Pfizer stock.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the earn-out and subsequent transactions related to stock appreciation rights and restricted stock units.

Pfizer's Chairman and CEO, Albert Bourla, executed stock appreciation rights, resulting in adjustments to his holdings of Pfizer common stock.

Executive Vice President Douglas Lankler reports the earn-out of stock appreciation rights and related transactions involving Pfizer common stock.

Payal Sahni, an Executive Vice President at Pfizer, reported the earn-out of stock appreciation rights and related transactions on February 22, 2025.

Executive Vice President of Pfizer, Sally Susman, reports the earn-out of stock appreciation rights and related transactions.

Christoffel Boshoff, President of R&D at Pfizer, reports the earn-out and subsequent tax-related withholding of shares related to stock appreciation rights and restricted stock units.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 625 phantom stock units through the company's Supplemental Savings Plan on February 13, 2025.

Director Ronald E. Blaylock reports purchasing Pfizer shares and transferring shares to a trust.

Christoffel Boshoff, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Pfizer's CEO, Albert Bourla, reported the acquisition of 75 phantom stock units through the Pfizer Supplemental Savings Plan on January 13, 2025.

Pfizer director James C. Smith acquired 1,696.193 phantom stock units as part of deferred compensation.

Pfizer director Cyrus Taraporevala acquired 1,413.494 phantom stock units as part of deferred compensation.

Rady A. Johnson, Executive Vice President of Pfizer Inc., reports changes in beneficial ownership due to the acquisition of phantom stock units under the company's Supplemental Savings Plan.

Pfizer director James Quincey acquired 1,460.611 phantom stock units as part of deferred compensation, which will be settled in cash or common stock upon retirement.

Pfizer director Shantanu Narayen acquired 1,884.659 phantom stock units as part of deferred compensation, which will be settled in cash or common stock upon retirement.

Pfizer director Joseph Echevarria acquired 1,743.309 phantom stock units representing deferred compensation.

Pfizer's CEO, Albert Bourla, acquired 20 phantom stock units through the company's Supplemental Savings Plan.

Pfizer's CEO, Albert Bourla, acquired 21 phantom stock units through the company's Supplemental Savings Plan, as detailed in a recent SEC filing.

Pfizer's Executive Vice President, Rady A. Johnson, acquired 7 phantom stock units through the company's Supplemental Savings Plan.

Pfizer's Executive Vice President, Rady A. Johnson, acquired 7 phantom stock units through the company's Supplemental Savings Plan.

Pfizer's CEO, Albert Bourla, acquired 20 phantom stock units through the company's Supplemental Savings Plan.

Pfizer's Executive Vice President, Rady A. Johnson, acquired 8 phantom stock units through the company's Supplemental Savings Plan.

Pfizer's CEO, Albert Bourla, acquired 21 phantom stock units through the company's Supplemental Savings Plan, as reported in a recent SEC filing.

Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the Supplemental Savings Plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of phantom stock units through the company's Supplemental Savings Plan.

Director Scott Gottlieb reported purchasing 1,000 shares of Pfizer stock at $28.24 on October 30, 2024.

Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the Supplemental Savings Plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 18 phantom stock units through the company's Supplemental Savings Plan.

Director Mortimer J. Buckley acquired 3,771.092 phantom stock units of Pfizer Inc. as deferred compensation under the company's Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.